A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Clinical trial NCT06680128 · RECRUITING

Trial details

NCT number: NCT06680128
Sponsor: SK Bioscience Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Japanese Encephalitis Virus Disease

Start date: 2025-02-24
Primary completion: 2026-06-26
Enrollment: 402

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.